Cerenome, Inc.

Cerenome, Inc. is a clinical-stage pharmaceutical company focused on developing, manufacturing, and commercializing treatments for cancer patients. Its lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere for solid organ cancers such as primary and secondary liver cancers via intra-arterial injection, and it develops and commercializes laboratory-developed tests including the CNSide Test, along with a data analytics and artificial intelligence platform for precision oncology and clinical decision-making. Formerly known as Plus Therapeutics, Inc., it changed its name to Cerenome, Inc. in August 2026, was founded in 1996, and is headquartered in Houston, Texas.